000063321 001__ 63321 000063321 005__ 20171129112117.0 000063321 0247_ $$2doi$$a10.1371/journal.pone.0101978 000063321 0248_ $$2sideral$$a98817 000063321 037__ $$aART-2014-98817 000063321 041__ $$aeng 000063321 100__ $$aSola, R. 000063321 245__ $$aEffects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: A multicenter randomized trial 000063321 260__ $$c2014 000063321 5060_ $$aAccess copy available to the general public$$fUnrestricted 000063321 5203_ $$aA dietary supplement (AP, Armolipid Plus) that combines red yeast rice extract, policosanol, berberine, folic acid, coenzyme Q10 and asthaxantine can have beneficial effects on cardiovascular disease (CVD) biomarkers. The aim of this study was to assess whether the intake of AP, in combination with dietary recommendations, reduces serum low density lipoprotein cholesterol (LDL-c) concentrations and other CVD biomarkers in patients with hypercholesterolemia. Eligible patients were recruited from the outpatient clinics of six Spanish hospitals Hospital Virgen del Roco (Sevilla); Hospital San Jorge (Huesca); Hospital San Pedro (Logroño); Hospital Gregorio Marañón (Madrid), Hospital la Fe (Valencia) and Hospital Universitari Sant Joan (Reus) as recruiting and coordinating center. 102 participants (mean age ± SD; 50.91±11.61; 32 men) with low CVD, with mild-to-moderately elevated LDL-c (between 3.35 mmol/L and 4.88 mmol/L) without hypolipemic therapy were randomized in a double-blind, parallel, controlled, multicenter trial commencing January 2012 and ending December 2012. Among the exclusion criteria were any concomitant chronic disease, triglycerides (TG) >3.97 mmol/L, pregnant or lactating, and history of CVD. At 12 weeks, compared to placebo, AP reduced LDL-c by -6.9%, apolipoprotein (Apo) B-100 by -6.6% and total cholesterol/HDL-c ratio by -5.5%, the ApoB/ApoA1 ratio by -8.6%, while increasing ApoA1 by +2.5% (p<0.05). AP consumption was associated with modest mean weight loss of -0.93 kg (95%CI: -1.74 to -0.12; P = 0.02) compared with control group while dietary composition remained unchanged in the AP group. The AP product was well tolerated. In conclusion, AP, combined with dietary recommendations, reduced LDL-c levels as well as total cholesterol/HDL-c and ApoB/ApoA1 ratios, while increasing Apo A1, all of which are improvements in CVD risk indicators. AP is a product which could benefit patients having moderate hyperlipidemia and excess body weight. 000063321 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000063321 590__ $$a3.234$$b2014 000063321 591__ $$aMULTIDISCIPLINARY SCIENCES$$b9 / 57 = 0.158$$c2014$$dQ1$$eT1 000063321 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000063321 700__ $$aValls, R. -M 000063321 700__ $$0(orcid)0000-0002-1309-4363$$aPuzo, J.$$uUniversidad de Zaragoza 000063321 700__ $$aCalabuig, J.R. 000063321 700__ $$aBrea, A. 000063321 700__ $$aPedret, A. 000063321 700__ $$aMorinã, D. 000063321 700__ $$aVillar, J. 000063321 700__ $$aMillán, J. 000063321 700__ $$aAnguera, A. 000063321 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDepartamento de Medicina, Psiquiatría y Dermatología$$cMedicina 000063321 773__ $$g9, 8 (2014), e101978 [10 pp]$$pPLoS One$$tPLoS One$$x1932-6203 000063321 8564_ $$s212362$$uhttps://zaguan.unizar.es/record/63321/files/texto_completo.pdf$$yVersión publicada 000063321 8564_ $$s124133$$uhttps://zaguan.unizar.es/record/63321/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000063321 909CO $$ooai:zaguan.unizar.es:63321$$particulos$$pdriver 000063321 951__ $$a2017-11-28-13:51:21 000063321 980__ $$aARTICLE